Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.

Pauline RiviereCaitlyn KantersGauthier PelletAlexander NiMarianne HupéNesrine AboulhamidFlorian PoullenotAlain BittonFrank ZerbibPeter L LakatosWaqqas AfifDavid LaharieTalat Bessissow

Published in: Inflammatory bowel diseases (2022)

This retrospective real-world data suggest that an anti-TNF agent as a first-line biological therapy is associated with higher rates of response at 3 months than ustekinumab in patients with CD.

Keyphrases

rheumatoid arthritis
primary care
cross sectional
electronic health record
stem cells
big data
machine learning
mesenchymal stem cells
bone marrow